Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK.

Watson RA, De La Peña H, Tsakok MT, Joseph J, Stoneham S, Shamash J, Joffe J, Mazhar D, Traill Z, Ho LP, Brand S, Protheroe AS.

Br J Cancer. 2018 Oct;119(9):1044-1051. doi: 10.1038/s41416-018-0300-x. Epub 2018 Oct 25. Review.

2.

No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer.

De La Pena H, Sharma A, Glicksman C, Joseph J, Subesinghe M, Traill Z, Verrill C, Sullivan M, Redgwell J, Bataillard E, Pintus E, Dallas N, Gogbashian A, Tuthill M, Protheroe A, Hall M.

Eur J Cancer. 2017 Oct;84:354-359. doi: 10.1016/j.ejca.2017.07.005. Epub 2017 Sep 1.

PMID:
28866371
3.

Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature.

Hickmott L, De La Peña H, Turner H, Ahmed F, Protheroe A, Grossman A, Gupta A.

Target Oncol. 2017 Apr;12(2):235-241. doi: 10.1007/s11523-017-0480-y. Review.

PMID:
28255845
4.

MHC class I-associated phosphopeptides are the targets of memory-like immunity in leukemia.

Cobbold M, De La Peña H, Norris A, Polefrone JM, Qian J, English AM, Cummings KL, Penny S, Turner JE, Cottine J, Abelin JG, Malaker SA, Zarling AL, Huang HW, Goodyear O, Freeman SD, Shabanowitz J, Pratt G, Craddock C, Williams ME, Hunt DF, Engelhard VH.

Sci Transl Med. 2013 Sep 18;5(203):203ra125. doi: 10.1126/scitranslmed.3006061.

5.

Quantum dots and carbon nanotubes in oncology: a review on emerging theranostic applications in nanomedicine.

Tan A, Yildirimer L, Rajadas J, De La Peña H, Pastorin G, Seifalian A.

Nanomedicine (Lond). 2011 Aug;6(6):1101-14. doi: 10.2217/nnm.11.64. Review.

PMID:
21955079
6.

The application of exosomes as a nanoscale cancer vaccine.

Tan A, De La Peña H, Seifalian AM.

Int J Nanomedicine. 2010 Nov 10;5:889-900. doi: 10.2147/IJN.S13402. Review.

7.

Roles for TGF-beta and programmed cell death 1 ligand 1 in regulatory T cell expansion and diabetes suppression by zymosan in nonobese diabetic mice.

Burton OT, Zaccone P, Phillips JM, De La Peña H, Fehérvári Z, Azuma M, Gibbs S, Stockinger B, Cooke A.

J Immunol. 2010 Sep 1;185(5):2754-62. doi: 10.4049/jimmunol.1001365. Epub 2010 Jul 30.

8.

Type 1 diabetes development requires both CD4+ and CD8+ T cells and can be reversed by non-depleting antibodies targeting both T cell populations.

Phillips JM, Parish NM, Raine T, Bland C, Sawyer Y, De La Peña H, Cooke A.

Rev Diabet Stud. 2009;6(2):97-103. doi: 10.1900/RDS.2009.6.97. Epub 2009 Aug 10.

9.

The prevention and treatment of cytomegalovirus infection in haematopoietic stem cell transplantation.

Tuthill M, Chen F, Paston S, De La Peña H, Rusakiewicz S, Madrigal A.

Cancer Immunol Immunother. 2009 Sep;58(9):1481-8. doi: 10.1007/s00262-009-0722-7. Epub 2009 May 23. Review.

PMID:
19466407
10.

Artificial exosomes as tools for basic and clinical immunology.

De La Peña H, Madrigal JA, Rusakiewicz S, Bencsik M, Cave GW, Selman A, Rees RC, Travers PJ, Dodi IA.

J Immunol Methods. 2009 May 31;344(2):121-32. doi: 10.1016/j.jim.2009.03.011. Epub 2009 Apr 1.

PMID:
19345222
11.

Highly purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient mice.

Bending D, De la Peña H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, Cooke A.

J Clin Invest. 2009 Mar;119(3):565-72. doi: 10.1172/JCI37865. Epub 2009 Feb 2.

Supplemental Content

Loading ...
Support Center